FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesThe Use of Direct-to-Patient Methods in Decentralized Clinical Trials in Israel
Topic: Direct-to-Patient
White Paper
Free
Import/Export of Clinical Supplies – An Overview
Topics: Logistics, Supply Chain
Webinar
Free
2023 US Conference - Sponsorship and Exhibitor Overview
Topic: Conference
Video
Free
